Chromatid scattering was observed in cervical cancer cells with increased PARP1 and PARP2 protein levels (HeLa, C33-A), suggesting that PARP1 and PARP2 protein levels could be used as a predictive biomarker for the efficiency of olaparib treatment, as previously proposed [60, 67]. The gene discussed is PARP2; the disease is cervical cancer.